Results. The mean UPDRS motor score for the sample was 39.2 (SDϭ12.93). At each stage of PD (from least to most involved), scores on functional measures indicated a significant and progressively reduced functional status. Limitations began early in the disease for the CS-PFP and FAR. Losses in performance were consistent across all stages of disease for the CS-PFP, FRT, 6MWT, and FAR. Several measures demonstrated meaningful losses of function only in later stages of disease. Findings extend current appreciation of functional limitations that begin early in PD and can guide the choice of functional outcome measures at different stages of disease severity.
Limitations. Data were obtained only from participants in H&Y stages 1 through 3 and only for some of the performance measures typically used.
Conclusions. The findings demonstrate that functional loss occurs at different points in the disease process, depending on the task under consideration. The resulting profile of functional limitations provides benchmarks that clinicians and researchers can use to interpret and monitor status of patients.
O verall ability to function declines over time in people with Parkinson disease (PD). Shulman and colleagues, 1 using the Unified Parkinson's Disease Rating Scale (UPDRS), were the first to examine functional differences by stage of PD. Because performance of basic functional activities is critical to maintaining independence and staving off disability, considerable effort has been directed toward investigating the effectiveness of physical intervention strategies for maintaining functional ability, despite the progressive nature of the disease. Based on the accumulated evidence, it is clear that early physical intervention can have positive benefits for these individuals. [2] [3] [4] [5] Although the UPDRS is the gold standard for quantifying response to interventions, 6 ,7 this scale does not adequately describe the patient's difficulties with physical function and participation and may be less responsive to rehabilitation interventions than to more specific measures of function. For this reason, a variety of performance measures have been used with people who have PD to examine response to exercise. Often included are measures of gross physical mobility 8 (eg, supine-to-stand maneuver), balance 9 13 ). However, ranges of typical values for these measures in patients with PD are lacking in the literature. There is a need for established benchmarks to allow clinicians and researchers to compare their data with points of reference, thus facilitating more meaningful interpretation.
This article reports typical values, by disease severity, for a variety of standard measures of function commonly used in exercise intervention studies and clinical practice. The profile of functional limitations at particular stages of disease severity is described based on both Hoehn and Yahr (H&Y) stages of disease, which is particularly useful for physical therapist clinicians, and UPDRS scores, the gold standard for researchers and neurologists. A greater appreciation of functional limitations associated with different stages of disease progression may guide timely initiation of rehabilitation interventions, with the goal of delaying functional decline. Established benchmarks can inform selection of measures for longitudinal tracking of function for people with PD.
Method Samples
The data in this report are from 3 studies conducted by Schenkman and colleagues at Duke University 8, 14 and the University of Colorado (unpublished) and from 2 studies conducted at Boston University by Ellis and colleagues 15 and TickleDegnen and colleagues. 16 Many of the measurements obtained in the 5 
The Bottom Line
What do we already know about this topic?
Several measures of physical function are available to clinicians and researchers to assess walking, balance, and general mobility in people with Parkinson disease. Despite the wide use of these measures, there is little information to guide the interpretation of the findings.
What new information does this study offer?
This study provides typical values for standard measures of walking, balance, and general mobility in people with Parkinson disease and describes the profile of functional limitations in relation to disease severity. This information provides established benchmarks to help clinicians and researchers interpret their findings when administering these measures.
If you're a patient, what might these findings mean for you?
Your physical therapist may administer physical performance tests to measure your walking ability, balance, and general mobility. The information presented in this article will help your physical therapist choose appropriate measures and compare your performance to the performance of other people with Parkinson disease. 15 except that the latter sample included a significantly higher proportion of patients with a graduatelevel education. Clinically, the cohorts were similar with regard to H&Y stage and UPDRS motor scores. The study by Ellis et al, 15 however, included patients with significantly longer disease duration and higher UPDRS total, UPDRS ADL, and 39-item Parkinson's Disease Questionnaire (PDQ-39) scores. 18 Qualityof-life scores, characterized with the 36-Item Short-Form Health Survey questionnaire (SF-36) 19 and PDQ-39, were consistent with mild to moderate disease severity.
Functional Measures
Measures of function were grouped into 3 categories: (1) overall functional capacity, (2) balance and gait, and (3) basic functional activities. Table 2 summarizes information related to administration and interpretation of these functional tests.
Where available, data are provided from older adults who were healthy for comparison.
Overall functional capacity was measured using the Continuous Scale Physical Functional Performance Test (CS-PFP). 20 -22 This standardized test of physical function was developed and validated on a large sample of older adults ranging from those living in assisted living environments to elite athletes. 20 Fifteen tasks are performed serially, providing a more realistic measure of overall capacity to carry out functional activities in the home setting than typically used single-task measures (eg, balance and gait measures). Performance would be expected to be better if a task is measured in isolation than if the task is measured in combination with 14 other tasks because of the physiological demands of continuous function. A higher score indicates greater functional capacity. On completion of the test, participants rated their perceived exertion 23 for the entire test.
Balance was measured using a variety of tests with established validity and reliability. For the FRT, 10,24 participants performed 2 practice trials followed by 3 test trials, which were averaged. For the TUG, 11,25-27 participants completed 1 practice trial followed by 2 test trials, which were averaged. 28 For the 360-degree turn in standing, participants performed one practice trial followed by 2 test trials, which were averaged. 8, 29 Gait function was assessed by means of the Two-Minute Walk Test (2MWT) and the 6MWT. The 2MWT required 2 practice walks due to an initial training effect. 30 Data from the third trial were analyzed. The 6MWT, originally developed as a measure of cardiovascular endurance, 31 has been applied to adults who were healthy and individuals with a variety of disorders, including PD. [31] [32] [33] [34] Data were obtained from a single trial.
Basic functional activities included measures of supine-to-stand time, stand-to-supine time, and functional axial rotation (FAR). Time required to lie supine on a bed from a standing position and to return to standing from the supine position was recorded following a single test. 8 For the FAR measure, 35 data were averaged from 2 trials to each side (left and right). No significant difference was detected between FAR to the right and the left (Pϭ.49); only data for FAR to the more limited side (worse measure) are reported.
PD Symptoms and Severity
Parkinson disease was diagnosed in each patient by a neurologist with fellowship training in movement disorders, with the exception of the small sample from Duke University, in which a general neurologist made the diagnosis. Severity of PD was measured using the UPDRS motor and total scores and the modified H&Y scale. 6 The on-state UPDRS and modified H&Y scores (scores when medications were most effective) were determined by a movement disorder specialist or by another professional trained by the study's movement disorder specialist. The UPDRS motor score provides a measure of severity of signs and symptoms (eg, bradykinesia, rigidity, tremor) of PD. Linear trends in performance measures were evaluated using linear regression. In order to test for a linear trend, new variables were created that were equal to the numerical categories of either UPDRS motor or H&Y scores (eg, 1, 2, 3, 4). These variables were included in the regression models, and the coefficients were interpreted as continuous covariates would be interpreted (eg, as a change in the outcome for a one-unit change in the category of UPDRS). The Cohen f statistic was used to report effect sizes of the estimated linear trends. An effect size of 0.15 is generally considered small, 0.4 medium, and 0.6 large. 37 All data analyses was performed using SAS/ BASE and SAS/STAT software, version 9.2 of the SAS System for Windows.*
Results

Characteristics of the Sample
The full database comprised 339 participants (Tab. 1 For the 360-degree turn (Fig. 2, eFig. 2), whether using the median or mean time, participants who were most involved (H&Y stage 3) took approximately twice as long to complete the task as those who were least involved (H&Y stages 1, 1.5, and 2), with mean time ranging from 3.32 to 7.34 seconds. Only about 2 seconds discriminated between participants who were least and most involved when measured with the UPDRS motor scores. In terms of number of steps, there was a difference of approximately 4 steps between participants who were least and most involved using either the H&Y stages or UPDRS motor scores.
Data from the 6MWT and 2MWT are shown in Table 3 , Figure 2 , and eFigure 2. Examining changes in 6MWT scores by H&Y stages, the median walk distance was 562 m for participants who were least involved and 389 m for those who were most involved, a difference of 173 m. The majority of this difference occurred between H&Y stages 2 and 2.5, with a difference of 100 m observed between median values. Mean scores showed a similar pattern. Examining 6MWT distance by UPDRS motor scores, the median score was approximately 200 m less for participants who were most involved compared with those who were least * SAS Institute Inc, 100 SAS Campus Dr, Cary, NC 27513-2414. † 1 inϭ2.54 cm. 
Basic Functional Activities
For the supine-to-stand task, the mean time to complete the task was not substantially different until H&Y stage 2.5 or UPDRS motor score 45.5 to 60 (Tab. 3; Fig. 3 ; eFig. 3, available at ptjournal.apta.org). When examining the supine-to-stand task by H&Y stage, the mean time to complete the task appears to discriminate supineto-stand times better than median times. The mean and median times for the supine-to-stand task were similar for the UPDRS motor scores. The pattern for stand to supine was similar to supine to stand, although the trend was for the mean time to be consistently slightly higher.
With respect to FAR, the mean and median values changed by approximately 20 degrees between H&Y stages 1 and 3 (Tab. 3, Fig. 3, eFig. 3). The drop in mean FAR across UPDRS motor scores was 36 degrees from lowest to highest, with a similar pattern for median values.
Discussion
These data provide expected ranges of physical function by disease severity for measures commonly used with individuals in early and middle stages of PD. We chose these measures because they capture many of the daily tasks that people with PD Table 3 . 
Functional Limitations and Task Performance in Early-and Middle-Stage Parkinson Disease
commonly bring to the attention of their health care providers, such as getting in and out of bed, rising from a chair, walking, maintaining balance, and turning to look behind while driving.
The data provide clinicians and researchers with a context for interpreting functional limitations of people with PD. Clinicians also can use the data to identify individuals who perform outside of anticipated mean and median scores for specific tasks. Furthermore, these data can inform decisions regarding appropriate measures for future studies of physical intervention.
We described the data in relation to 2 different measures typically used to characterize PD severity: the UPDRS motor score and the modified H&Y scale. 6 The UPDRS is the gold standard for experimental studies and medical management; however, extensive training is required to use this measure appropriately, it is time intensive, and the scope of information gathered is beyond that required for decisions related to physical intervention. In contrast, the H&Y score provides only a coarse estimate of disease progression but is more accessible to physical therapists. For these reasons, we chose to examine physical activities in relation to both measures. Several insights related to the level of disease severity at which functional decline begins to emerge, choice of measures at different points in the disease course, and interpretation of measures emerged from this work. The first insight is that activity limitations occur very early in PD, as indicated by the CS-PFP, becoming progressively worse as the disease advances. This finding is of importance because most measures used with people who have PD are not as clearly responsive to early limitations in activities as is the CS-PFP.
Individuals with PD had lower CS-PFP scores compared with individuals who were healthy in the study by Cress and Meyer. 22 These scores represent a substantial loss of functional capacity. Those individuals with H&Y stage 3 scores (mean ageϭ69 years) had CS-PFP scores below 30, more than 25 points lower than scores of individuals who were healthy, indicating even greater loss of capacity.
The CS-PFP is a unique measure because it quantifies capacity for performance of daily functional activities. 22 As such, this test is more likely to identify limitations that would be missed in performance of a few single tasks such as those typically used to quantify function (eg, FRT, TUG). Furthermore, the tasks included in the CS-PFP encompass a broad range of activities required for daily function.
Data from a variety of studies suggest that transition from independence to dependence occurs around a CS-PFP score of 57. 22 As evidenced by median scores, a substantial number of participants in our data set had reached or exceeded this threshold by H&Y stage 2.5 and UPDRS motor score of 30.5 to 45. These findings are consistent with data of Shulman and colleagues 1 indicating a transition from preclinical disability and disability occurs for people with UPDRS total scores above 50.
It should be noted that the transition to disability specific to people with PD has not yet been established. Because time to complete tasks is important in scoring the CS-PFP, bradykinesia probably affects the overall scores substantially, bringing individuals to the transition point (score of 57) established for older adults, even though they may not be approaching disability. Nevertheless, these data underscore the degree to which PD affects overall physical capacity even very early in the disorder.
Of interest, most of these individuals continue to perform within a relatively constant rate of perceived exertion as evidenced by their RPE of Յ12, consistent with the range observed in older adults who are 34, 41, 42 In the context of gait The fourth important point relates to clinical and research recommendations for selection of functional measures across stages of PD. Choice of measures will necessarily be dictated by the purpose for which they are to be used. In the clinic, physical therapists managing patients in the early stages may consider using the CS-PFP and the FAR to identify deficits in status. The 6MWT and the FRT also could be incorporated early in the disease to establish baseline status and repeated periodically thereafter to determine performance relative to elderly people who are healthy and to expected ranges in PD. The TUG, 2MWT, and supine-to-stand measure should be reserved for patients in the moderate stages.
For intervention studies, choice of measures should be determined by both stage of PD and study length. For participants in the earliest stage of PD, only the CS-PFP and FAR detected differences from ageappropriate norms. Thus, for such participants, these 2 measures have potential to detect change of functional problems in short-term studies (less than 6 months). Conversely, other measures have low potential to detect functional problems in shortterm studies in which participants are in early stages of PD. Because of the lack of responsiveness of most measures for people in the earliest stages of PD, a new measure of function, the instrumented Timed "Up & Go" Test (iTUG), 47 has been developed. The iTUG appears to be especially sensitive to deficits in balance and may provide further insight into these deficits in the earliest stages of PD.
Many of the measures in addition to the CS-PFP and FAR might be appropriate for longer-term studies (eg, 12-24 months), even when people in early stages of PD are included. Examples of such measures are the FRT and 6MWT, which could add
insight into functional change as the disease progresses. The TUG, 2MWT, and supine-to-stand measure would be appropriate for studies including participants who have moderate to severe PD either at baseline or at the end of the study.
Several limitations should be acknowledged. First, most of the participants in this database were in H&Y stages 2, 2.5, and 3, with only 3% in stages 1 to 1.5. These findings were in part because people are not always diagnosed in the earliest stages of PD, and of those who are, not all are referred for exercise interventions. Second, because these data are cross-sectional (not longitudinal), we cannot make statements about change over time. Nevertheless, these data give some insight into what to expect at each point in the disease process and can help clinicians determine which deficits begin in the earliest stages as well as which measures might be of most use early in the disease process. Future investigations, utilizing change scores will be essential to further our understanding of performance in people with PD. Third, these data were derived from 5 different studies, and not all measures were performed at all sites and for all studies. Nevertheless, the sample was of sufficient size that the number of participants ranged between 100 and 252 for all measures. Finally, the participants were predominantly educated and white, with low diversity with respect to income and race, limiting ability to generalize to some extent. However the samples were recruited from 3 distinct locations across the United States, increasing generalizability from a geographical perspective.
In summary, typical values are presented relative to disease severity for standard measures of functional ability commonly used by researchers and clinicians who work with indi- The parent studies from which data were obtained for this study were approved by the institutional review boards of Boston University, Duke University, and the University of Colorado. 
